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CRISPR-cas system: biological function 
in microbes and its use to treat antimicrobial 
resistant pathogens
Muhammad Abu Bakr Shabbir1, Muhammad Zubair Shabbir3, Qin Wu2, Sammina Mahmood4, Abdul Sajid1,5, 
Muhammad Kashif Maan1, Saeed Ahmed1, Umer Naveed6, Haihong Hao1* and Zonghui Yuan1,2*
Abstract 
The development of antibiotic resistance in bacteria is a major public health threat. Infection rates of resistant patho-
gens continue to rise against nearly all antimicrobials, which has led to development of different strategies to combat 
the antimicrobial resistance. In this review, we discuss how the newly popular CRISPR-cas system has been applied to 
combat antibiotic resistance in both extracellular and intracellular pathogens. We also review a recently developed 
method in which nano-size CRISPR complex was used without any phage to target the mecA gene. However, there is 
still challenge to practice these methods in field against emerging antimicrobial resistant pathogens.
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Introduction
Antibiotic compounds have significantly impacted on 
modern medicine since their first introduction approxi-
mately 90 years ago. While antibiotics can overcome pre-
viously fatal infections, their irrational use in veterinary 
and agricultural fields poses a major threat as it results 
in tremendous flow of antibiotics into the environment 
[1]. This exposure of many antibiotics leads to enormous 
selective pressures that drive the spread and evolution of 
antimicrobial resistance genes in pathogenic and com-
mensal bacteria [2, 3]. These antibiotic resistant genes 
enable bacteria to overcome antibiotics via different 
mechanisms, including the use of efflux pump, antibiotic 
molecule deactivation by enzymes, and chemical modi-
fication (ribosome and cell wall) to protect the cellular 
targets of antibiotics [4]. Taken together, these resistance 
mechanisms pose a threat to the efficacy of antibiotics 
used therapeutically [3]. The Center for Disease Con-
trol and Prevention reported in 2013 that antimicrobial 
resistant (AMR) pathogens infect more than 2 million 
people each year, resulting in 23,000 deaths [5]. It is also 
predicted that drug resistant pathogens will cause 10 mil-
lion fatalities per year by the year 2050. This means drug 
resistant pathogens will cause more deaths than traffic 
accidents, diabetes and cancer [6]. A contributing factor 
to the development of antibiotic resistance is the ability 
of bacteria to adopt incredible phenotypic and genotypic 
heterogeneity for survival in adverse environments [6].
The main factor for AMR is the decline in novel anti-
biotic production: no new antibiotic class has been 
approved for Gram-negative bacterial infections in more 
than 45  years, and only 37 antibiotic drugs are cur-
rently in phase II or III clinical trials [7]. Further, anti-
biotic development, screening and testing is expensive 
and intensive resources are required [8]. These factors 
forced our hands to search for alternative treatments for 
AMR pathogens, including the development of a unique 
antibacterial arsenal with precise target capabilities. To 
achieve this, researchers have developed novel peptide 
and nucleic acid based antibacterials, bacteriophage ther-
apies, bacteriocins, antibodies and anti-virulence com-
pounds, among others [7]. In our review, we discuss the 
adaptive immune system of bacteria. Clustered regularly 
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interspaced short palindromic repeats (CRISPR) system, 
and its role to overcome the growing AMR threat.
Three types of CRISPR‑cas system
The story of CRISPR-cas system began in 1987 when 
Nakata and colleagues reported a set of 29 nucleotide (nt) 
repeats in E. coli during their study of the iap gene [9]. 
By sequencing numerous microbial genomes in the next 
decade, additional repeat elements from the genomes 
of different archaeal and bacterial strains were also 
reported. Later, this unique family of inter-spaced repeat 
sequences were termed as clustered repeat elements 
[10]. In 2002, the term CRISPR was used by Mojica and 
Jansen [11]. A major breakthrough was in 2005, when 
spacer sequences were separated from direct repeats 
suggesting their phage association or extrachromosomal 
origins [12, 13]. In 2010, the basic function and mecha-
nism of CRISPR-cas system has become clear. This sys-
tem is comprised of a genetic locus with non-repetitive, 
spacer sequences and adjacent 6–20 genes that encode 
CRISPR-associated (cas) proteins [14, 15]. A number of 
researchers have begun to use the CRISPR-cas system 
for biotechnological applications and the generation of 
phage resistant dairy cultures [11].
The CRISPR-cas system is an adaptive immune system 
of bacteria and archaea, which protects the bacteria from 
invaders, including bacteriophages or phages and mobile 
genetic elements (MGEs) [16]. The CRISPR-cas system 
degrades foreign genetic elements in three steps (Fig. 1). 
Adaptation or spacer acquisition [17] is the first stage 
Fig. 1 Mechanism of CRISPR-cas immunity divided into three stages. Stage 1: Spacer acquisition. In the first stage specific fragments of virus 
or plasmid double stranded are integrated at the leader end of CRISPR array on host DNA. A CRISPR array consists of unique spacer (red box) 
interspaced between repeats (blue box). Spacer acquisition occurs in the presence of cas1 and cas2 proteins, which are present near the vicinity of 
CRISPR array. Stage 2: Biogenesis of crRNA. In this stage RNA polymerase at leader end helps in the transcription of Pre-CRISPR RNA (Pre-crRNA) to 
mature crRNA. Stage 3: Interference. In the final stage, specific match between crRNA spacer and target sequence leads to the cleavage of foreign 
genetic elements (blue and red strips) [14, 15]
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in which spacer sequence after recognition is integrated 
into the CRISPR array. The second stage is biogenesis 
or expression of CRISPR RNA (crRNA), in which pre-
CRISPR RNA (pre-crRNA) are transcribed by RNA poly-
merase (RNAP). These pre-crRNA are then cleaved into 
the small crRNA by specific endoribonucleases. Based 
on the crRNAs function, these are also known as guide 
RNAs [18, 19]. Interference [20] is the final stage in which 
crRNAs recognize and form base pair specific to foreign 
RNA or DNA with almost perfect complementarity [14, 
15]. This leads to the cleavage of the crRNA-foreign 
nucleic acid complex. Conversely, if there is any muta-
tion in proto-spacer adjacent motif (PAM) or mismatch 
between spacer and invader’s DNA, the cleavage does not 
occur and the host is susceptible to infection [21].
The CRISPR-cas system is divided into three subtypes: 
CRISPR-cas system type I, II and III. This classification 
was made on the basis of signature genes present in each 
type. For example, type I has cas3, type II has cas9 and 
type III has cas10 gene. However, it is important to note 
that all types and subtypes of CRISPR system have cas1 
and cas2 proteins, since these two proteins play a key 
role in spacer [14, 15]. CRISPR-cas system types present 
in different bacterial species of interest are provided in 
Table 1.
Type I system
CRISPR-cas type I system is present in most bacteria and 
archaea [25]. This system is further divided into six sub-
types (A–F) encoding cas3 gene. Cas3 is a multi-domain 
protein with helicase and nuclease activity [42]. The 
Cas3 protein contains two domains: an N-terminal HD 
phophohydrolase for cleavage of DNA and a C-terminal 
DExH helicase domain to unwind double stranded DNA 
[14, 15]. These two domains work together to degrade 
invader DNA. However, cas3 alone is not able to iden-
tify invader’s DNA and protect cells from infection [18, 
43]. In each subtype of the type I system, a number of 
specific subtype cas proteins assemble to form a com-
plex known as crRNA guided surveillance complex or 
CRISPR associated complex for antiviral defense (CAS-
CADE). These complexes play a role in the identification 
and binding of target sequence complementary to the 
crRNA spacer. The crRNA guided surveillance complex 
was first described in E. coli K12 (type I-E) [18, 43]. The 
complex is a combination of five cas proteins. Cas6e (pre-
viously named as Cse3 or CasE) helps in the maturation 
of crRNA. The mature crRNA remains attached to the 
CASCADE complex and has a role in the detection and 
cleavage of invader DNA [14, 15]. Similar type of com-
plex was also reported in S. solfataricus [44]. Addition-
ally, crRNA guided surveillance complexes have been 
identified in Pseudomonas aeruginosa (type I-F) [45] and 
Bacillus halodurans (type I-C) [46].
Type II system
This system is present only in bacteria [25]. Compared 
to other CRISPR-cas types, the type II system is the sim-
plest [21]. The CRISPR-cas type II system has four genes: 
cas1, cas2, cas9, and cas4 in the case of type II-B or csn2 
in the case of type II-A. The characteristic protein of the 
type II system is cas9, which has a role in both crRNA 
biogenesis and cleavage of invader DNA [35]. The cas9 
gene consists of two domains: RuvC and HNH domains 
[47]. The HNH domain helps in cleavage of DNA which 
is complement to crRNA guide, while the RuvC domain 
is involved in the cleavage of non-complement strand 
[47]. The biogenesis of crRNA in type II system requires 
a trans-activating crRNA (tracrRNA). The encoding of 
tracrRNA in Streptococcus pyogenes take place at the 
opposite strand of CRISPR-cas locus [14, 15]. Hybridi-
zation between crRNA repeats and tracRNA leads to 
the formation of double stranded RNA (dsRNA), which 
is identified and cleaved by cellular non-cas RNase III 
enzyme. The biogenesis of crRNA is inhibited by the 
deletion of cas9 gene; however, its role in crRNA biogen-
esis is unclear [35]. Jinek and colleagues demonstrated 
that cas9 enzyme requires both tracrRNA and crRNA 
for the cleavage of target DNA [47]. Notably, all domains 
necessary for DNA cleavage are fused in a single protein 
(cas9), which makes the CRISPR-cas type II system an 
ideal choice for genome manipulation [48].
Type III system
Type III system has been divided into two subtypes: type 
III-A and type III-B [25]. This system is most commonly 
present in archaea, but it was also reported that the type 
III-B system is present only in conjunction with other 
CRISPR types. The CRISPR-cas type III system encodes 
both cas6 and cas10 genes. Cas10 is also known as repeat 
associated mysterious protein (RAMP), and is potentially 






Type I E. coli, P. aeruginosa, M. xanthus, B. halodurans, 
C. concisus, C. curves, C. fetus, C. hominis, C. 
rectus, Y. pestis, Salmonella specie, E. amylovora, 
P. acnes
[18, 22–29]
Type II S. thermophilus, S. mutants, N. meningitides, C. 
jejuni, L. pneumophila, L. monocytogenes, F. 
novicida, S. pyogenes, S. aureus, M. gallisepti-
cum, E. faecalis
[21, 30–38]
Type III P. furiosus, S. epidermidis, M. tuberculosis [39–41]
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involved in the maturation of crRNA and DNA cleavage 
[49]. Cas6 is an endoribonuclease which is not associ-
ated with CASCADE complex and works independently 
[50]. The CASCADE complex of type III system binds 
with mature crRNA and cleaves foreign RNA [51]. Fur-
thermore, cas6 might be shared in those archaea which 
have type III system along with CRISPR-cas type I-A or 
I-B [52].
Although these two subtypes of type III CRISPR-cas 
system have similarities, it appears that these two sys-
tems target chemically different substrates. For example, 
type III-A system of S. epidermidis targets DNA while 
type III-B system present in S. solfataricus and Pyrococ-
cus furiosus cleave RNA [14, 15]. This shows the diversity 
of CRISPR system present within the type III systems.
Role of CRISPR‑cas system in bacterial virulence
Several studies have shown that the CRISPR-cas system 
has additional functions apart from defending bacteria 
against invaders. This system also controls endogenous 
transcription and is involved in the regulation of bacte-
rial pathogenicity. For example, Francisella novicida, a 
possible causative agent of disease in humans, replicates 
intracellularly by bypassing the host immune system. 
This bacterium has several mechanisms to subvert host 
macrophages and other immune cell functions. Upon 
the engulfment by macrophages, F. novicida enters the 
phagosome, a compartment having several antimicro-
bials and immune recognition receptors [53]. Toll-like 
receptor 2 (TLR2) is one of those receptors that can 
detect bacterial lipoproteins (BLPs) [34]. Activation of 
TLR2 initiates a pro-inflammatory response and recruits 
as well as activates immune cells, this ultimately helps 
in clearing the bacterial pathogen. F. novicida uses cas9, 
sacRNA (small, CRISPR associated RNA) and tracrRNA 
as regulators to repress the BLP expression [31]. Thus, 
this pathogen can survive within the host by preventing 
the activation of TLR2. However, F. novicida induces sig-
nificant inflammatory response in the absence of these 
regulators, as it was reported that cas9, sacRNA and trac-
rRNA deletion mutants elicits a significant inflammatory 
response compared to wild type [31]. Additionally, it has 
also been reported that these mutants were not able to 
productively infect mice, further emphasizing the impor-
tance of CRISPR-cas system as a virulence regulator in F. 
novicida [31].
It was also reported that Neisseria meningitides uses 
cas9 for attachment to host cell surface and intracellu-
lar replication [31]. In addition, it has been reported that 
Campylobacter jejuni uses cas9 for attachment as well 
as for invasion in epithelial cells [32]. We hypothesize 
that the CRISPR-cas system not only facilitates C. jejuni 
attachment to host cells, but also protects this bacte-
rium from the host’s innate complement system. Further, 
deletion of cas9 gene in cst-II positive C. jejuni results in 
almost complete loss of virulence [32]. The exact mech-
anism by which cas9 gene regulates virulence in these 
microorganisms is not yet known, but it is hypothesized 
that cas9 does not work alone to control virulence prop-
erties. Recently, a study reported that CRISPR-cas9 gene 
has a role in the regulation of several virulence associated 
genes and increases the virulence of C. jejuni [54].
CRISPR‑cas system involvement in antimicrobial 
resistance
There are several studies implicating the CRISPR-cas sys-
tem in antimicrobial resistance. For example, this system 
promotes envelope integrity of F. novicida by the regula-
tion of BLP. This leads to the development of resistance 
against several membrane stressors, including antibiot-
ics [55]. A separate study found a relationship between 
competence systems (promotes gene acquisition) and 
CRISPR system: Aggregatibacter actinomycetemcomitans 
competent strains have CRISPR-cas systems, while non-
competent bacterial strains lost their CRISPR immune 
system [56]. This finding revealed that the evolution of 
competence system and CRISPRs promotes genetic het-
erogeneity and the rise of new bacterial species. Similarly, 
it was suggested by Levin et al. [57] that bacteria having 
a CRISPR system might acquire resistance which could 
result in a population of bacteria with greater fitness than 
other variants.
It is also important to note that CRISPR system pro-
tects the host genome against invaders to maintain 
genetic homeostasis [58, 59]. Foreign genetic elements, 
such as plasmids and other conjugative elements, may 
carry beneficial genes that may increase bacterial fit-
ness in the environment, such as virulence and antibiotic 
resistance.
Several studies have found a negative correlation 
between CRISPR-cas system and the presence of plas-
mids and phages, as explained in Enterococcus, Campylo-
bacter and many group A Streptococcus species [60]. One 
study found that targeting of plasmid by CRISPR-cas sys-
tem results in untoward effect in S. epidermidis regarding 
its antibiotic resistance [58, 61].
Why CRISPR‑cas system used to encounter 
antibiotic resistance threat?
Four major classes of DNA binding proteins have been 
engineered to achieve effective genome editing: mega-
nucleases originated from microbial MGEs [62], tran-
scription activator like effectors (TALEs) derived from 
bacteria (Xanthomonas) [63], Zinc finger nucleases 
(ZFNs) from eukaryotic transcription factors [11] and 
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finally the RNA guided DNA endonucleases cas9 from 
CRISPR-cas type II system of bacteria [48].
Genome editing by meganucleases is not widely used 
due to low sequence specificity for target DNA [11]. 
ZFNs also have limitations, as they are difficult to design 
for binding to a desired sequence. Furthermore, ZFNs 
have limited target site selection. TALENs are easy to 
design due to their capacity to have longer DNA binding 
protein domains, allowing for high specificity of target-
ing. However, TALENs are much larger than ZFNs, and 
this size poses a complication for delivery into cells [64].
The Cas9 nuclease of the CRISPR-cas type II system 
uses a guide RNA to identify target DNA by Watson–
Crick base pairing. Sequences present in CRISPR guide 
RNAs are specific to an invader sequence, meaning this 
sequence can be easily replaced by our desired sequence 
to retarget the CRISPR-cas9 nuclease [11].
Detailed study of the CRISPR-cas system has enabled 
researchers to insert, delete and mutate desired genes 
in virtually any species, and can even be used to correct 
genetic diseases in live animals [65]. Additionally, this 
system is now used in specific antibacterial preparations 
that can target AMR pathogens within complex popula-
tions of bacteria, allow antibacterial delivery to patho-
genic bacteria, and in some cases deliver treatments to 
host cells infected with pathogenic bacteria. The CRISPR-
cas system distinguishes between commensal and patho-
genic bacterial species due to sequence specific targeting. 
The potential of CRISPR-cas system to counteract AMR 
pathogens is highlighted here.
Irony: bacterial defense system against their own 
kind
The CRISPR-cas system can differentiate between com-
mensal and pathogenic species due to highly specific 
sequence targeting. CRISPR guide RNAs can be designed 
to target virulence and chromosomal genes which are 
specific to pathogens, thereby enabling the CRISPR-
cas system to be repurposed against bacteria instead of 
defending against invaders [66]. CRISPR-cas9 technol-
ogy can be used to produce sequence specific antibiot-
ics with the ability to target only AMR pathogens [67]. 
Cas9 is a double stranded DNA nuclease that can be pro-
grammed or used to cleave any DNA sequence [67]. Pre-
viously, scientists transformed E. coli and Staphylococcus 
aureus with a plasmid encoding cas9 guided RNAs that 
precisely degraded antibiotic resistant genes [47, 68]. 
Cas9 programmed with specific target sequences can 
enhance the cytotoxicity of resistant cells. This means 
AMR pathogens can be reverted to antibiotic sensitive 
cells by precise cleavage of resistant genes with the help 
of CRISPR-cas9 system.
The major obstacle in CRISPR-cas9 antibacterial deliv-
ery is delivering the complex (160-kDa protein-RNA) 
through the membrane of bacteria. In addition, how can 
this complex be delivered to both Gram-positive and 
Gram-negative bacteria? To solve this problem, many 
researchers used species-specific phages as vehicles for 
CRISPR-cas delivery. Phages are natural predators of bac-
teria that inject their DNA into bacteria. In 2014, it was 
reported that CRISPR-cas9 designed to target specific 
chromosomal genes of bacteria can be encapsulated into 
the capsids (protein coat) of inert phages by genetically 
encoding the phagemid. Phagemid is a plasmid designed 
to be packaged into the capsids of phage [69]. Another 
study reported that genetically modified phage having 
CRISPR-cas9 can target antibiotic resistance in S. aureus 
[70]. Taken together, these findings showed that CRISPR-
cas9 antibacterials are highly specific for pathogenic bac-
teria and spare non-pathogenic species, which is a basic 
requirement for the development of new novel antibiot-
ics. These in vitro findings highlight the attractiveness of 
phages as a means for CRISPR-cas9 delivery for the rapid 
killing of resistant pathogens.
Moreover, other groups have explored the potential 
of CRISPR-cas9 in removing resistant bacteria from 
complex bacterial populations [71]. Further work has 
engineered phage scaffolds to increase the host range 
expansion [72], and others have explored gene editing 
strategies to re-sensitize bacteria against antibiotics [65]. 
These results support the repurposing of CRISPR-cas9 
machinery to be used against AMR infections and newly 
emerging bacterial strains. The CRISPR-cas9 is highly 
adaptable and programmable by altering the sequence of 
guide RNA. However, the methods used for encapsula-
tion of both sgRNA and protein limit their practical use 
because of low loading and packaging efficiencies. Addi-
tionally, a requirement for high administration dosage 
may cause toxicity problems [73, 74].
To circumvent these problems, recent work has devel-
oped a method of non-viral genome editing, in which 
they successfully used nano-sized CRISPR complex to 
target the mecA gene. They used polymer derived cas9 
protein which is a covalently modified with cationic pol-
ymer. They claimed that nano-sized CRISPR complex 
(Cr-Nanocomplex) were successfully formed without 
disturbing the CRISPR-cas9 activity of DNA cleavage. 
Cr-Nanocomplex specifically designed to target mecA 
gene. This gene is involved in methicillin resistance and 
can be delivered efficiently into the methicillin-resist-
ant S. aureus (MRSA), and allow the efficient bacterial 
genome editing than the native cas9 complex or tradi-
tional lipid based formulation [75]. This work strongly 
suggest that CRISPR-cas9 can be repurposed to attack 
AMR pathogens.
Page 6 of 9Shabbir et al. Ann Clin Microbiol Antimicrob           (2019) 18:21 
However, these methods only address external and 
topically treated infections, like MRSA. Therefore, other 
strategies are needed for systemic intracellular pathogens 
to treat tissue and organ specific infections.
Intracellular delivery of CRISPR‑cas9 antibacterials
As previously explained, genetically encoded phage 
genomes can be used to deliver CRISPR-cas9 antibacteri-
als into bacteria. When pathogenic bacteria are intracel-
lular, the delivery of CRISPR-cas9 antibacterials becomes 
more challenging. In this scenario, CRISPR-cas9 encoded 
in phage must be used to specifically target infected cells, 
before its release into the bacteria residing within the 
cells. This delivery process is complicated by a specificity 
for both layers (host cell and intracellular bacteria) [8] as 
shown in Fig. 2.
After the development of new drug, its effectiveness 
to the matrices for efficient delivery and therapy are the 
greatest challenge. The modification of chemical proper-
ties of a drug for delivery reduces the treatment cost with 
some additional benefits, such as the bypassing of healthy 
cells and a lower dosage requirement. There are multiple 
approaches to use CRISPR-cas9 to edit the human host 
cell [76]. However, these strategies only deal with human 
target cells and do not address the challenges associ-
ated with delivery of CRISPR-cas9 encoded in phages to 
combat intracellular infections. Additionally, variation in 
size and structure of different phages needs to be consid-
ered. To overcome these challenges, CRISPR-cas9 offers 
a strategy that can help in the development of program-
mable antibacterials that can be modified genetically into 
a phage genome. Furthermore, delivery of CRISPR-cas9 
into infected host cells by encoded phages provides an 
advancement over currently available delivery strategies.
It is known that phages have structural diversity; there-
fore, traditional strategies such as the use of nanoparticles 
as cargo are not practical. Different porous nanoparticles 
are used as cargo for drug delivery, but these methods are 
not effective when large and non-symmetrical phages are 
used due to limitations in pore size. To solve these issues, 
it is necessary to encapsulate bacteriophages to stabilize 
them for therapeutic purposes; previous work has shown 
it is possible to directly induce the self-assembly of phage 
encapsulation (bacterial cargoes) into lipid and silica 
based particle structures [77]. Chemical formulations to 
encapsulate, such as doping in silica and stabilizing pro-
teins, can be modified by the use of different biological 
components. Silica based encapsulated phages can evade 
the immune system while retaining normal biological 
function. This strategy can help overcome the twofold 
barrier problem to treat intracellular bacterial infections 
such as Burkholderia pseudomallei.
CRISPR-cas9 encoding phages provide the oppor-
tunity for species-specific delivery of antibacterials. 
Fig. 2 a, b CRISPR-cas9 antibacterials delivery to infected cell. a CRISPR-cas9 antibacterials encoded in bacteriophages. b CRISPR-cas9 encoded in 
phages were then introduced into the infected host cells to combat AMR pathogens
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Furthermore, CRISPR-cas9 adaptability allows for rapid 
development of biologics to counteract AMR pathogen 
infections. It is now possible to build CRISPR-cas9 guide 
RNAs library to combat rapidly evolving AMR pathogens 
[8].
Summary
AMR pathogens are a major public health concern world-
wide. Different strategies have been developed to counter 
the rise of AMR. Among them, a newly developed tech-
nique known as CRISPR-cas system brings an arsenal in 
the warfare against resistant pathogens. With the help 
of CRISPR-cas system, scientists treat both extracellu-
lar (MRSA infection) and intracellular (B. pseudomallei) 
antibiotic resistant pathogens. However, it is still a chal-
lenge to apply CRISPR-cas9 antibacterials against non-
laboratory resistant pathogens.
Future perspective
1. Choosing a suitable combination of temperate and 
lytic phages being specific for sensitized pathogens is 
a big challenge. Thus there is a dire need to develop a 
universal means for efficient delivery of DNA into all 
pathogens.
2. Phages encoded with CRISPR-cas9 should also be 
used in non-laboratory strains without disrupting the 
native healthy microbiomes.
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